Blood Transfus 2012; 10: 112-3 DOI 10.2450/2011.0064-11 © SIMTI Servizi Srl Dear Sir, In their timely letter on the current state of haemophilia therapy, Calizzani and Arcieri1 tackle two clinically important points: the effect of the source of factor VIII replacement therapy (plasmaderived or recombinant) on the cumulative incidence of factor VIII inhibitors in patients with haemophilia A; and...

BACKGROUND Experience of liver transplantation in haemophiliacs with end stage hepatitis C liver disease is limited and particularly difficult questions are raised when there is also HIV infection. AIMS This is the first report in Great Britain to describe the operative replacement therapy and initial outcome in four haemophiliacs with end stage HCV cirrhosis. PATIENTS Two patients had fact...

Central nervous system hemorrhage is an uncommon and potentially devastating event in hemophiliacs, with an incidence of 2-8%.1 Intraspinal hematomas account for 8.5% of CNS hemorrhages in patients with factor VIII or IX deficiencies.2 Although most reported cases in this population are secondary to trauma, there are a few reports of spontaneous hemorrhage.3,4,5 We present a case of spontaneous...

Apparently quiescent, nonapoptotic endothelial cells mediate the activation of factor X by activated factor IX in the presence of its cofactor, activated factor VIII. In a previous study, we reported that during the activation of factor X, the interaction of the cofactor with the endothelial cell membrane clearly differs from the interaction of the cofactor with artificial lipid membranes. In t...

the prevalence of non-alcoholic fatty liver disease (nafld) has markedly increased, especially in patients exhibit one or more features of the metabolic syndrome. this study investigates the effect of rosuvastatin (rsv) and/or b-carotene (bc) in nafld-induced rats. rats were classified into nine groups; normal (i), nafld-induced with high-fat diet (hfd; ii), nafld switched to regular diet (rd; ...

ACQUIRED HEMOPHILIA A occurs as a result of development of inhibitory autoantibodies to factor VIII in the coagulation cascade. These antibodies result in impaired hemostasis and bleeding disorders of variable severities through varied mechanisms including impairment of binding of factor VIII to membrane phospholipids, factor IX, and/or von Willebrand factor. Common presentation includes mucocu...

Introduction: Hemophilia A is an inherited disease caused by a deficiency of factor VIII, which results from a genetic inheritance located on the X chromosome. During treatment of patients with this disorder, factor VIII inhibitors may be present, which are primarily antibodies type immunoglobulin G (IgG), and interfere with the activation of factor VIII. Objectives: The present study aims to i...

BACKGROUND Indications, efficacy, and safety of plasma products are highly debated. We compared the concentrations of haemostatic proteins and cytokines in solvent/detergent-treated plasma (SDP) and fresh-frozen plasma (FFP). METHODS Concentrations of the following parameters were measured in 25 SDP and FFP samples: fibrinogen (FBG), factor (F) II, F V, F VII, F VIII, F IX, F X, F XIII, von W...

Fulminant hepatic failure (FHF) in humans produces a bleeding diathesis due in large part to a reduction in the biosynthesis of liver-derived coagulation factors. Remarkably, factor VIII procoagulant activity is elevated in most of these patients despite widespread liver cell death. FHF can be modeled in mice by administration of azoxymethane, the active ingredient found in cycad palm nuts. We ...